Gilles Courtemanche

Raw data of 'identification of drugs and promising starting points for drug discovery from an FDA-approved library'

Bruno S. Pascoalino, Gilles Courtemanche, Marli Tenório Cordeiro, Laura H. V. G. Gil et autres

Background The recent epidemics of Zika virus (ZIKV) implicated it as the cause of serious and potentially lethal congenital conditions such microcephaly and other central nervous system defects, as well as the development of the Guillain-Barré syndrome in otherwise healthy patients. Recent …

br, fr (code pays fourni par la source)

Acinetobacter baumannii: Setup and characterization of pneumonia and septicemia preclinical models with longitudinal monitoring using bioluminescent strains

Abdessalem Rekiki, Mohit Saxena, Aurore Gaudin, Ioanna Théodorou et autres

International audience

The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to Plasmodium falciparum parasite resistance

James M. Murithi, Cécile Pascal, Jade R. Bath, Xavier Boulenc et autres

NSG mouse model, MMV688533 displays a long-lasting pharmacokinetic profile and excellent safety. Selection studies reveal a low propensity for resistance, with modest loss of potency mediated by point mutations in PfACG1 and PfEHD. These proteins are implicated in intracellular trafficking, lipid utilization, …

us, fr, es, au, ch, th, gb, id, Ouganda, in (code pays fourni par la source)

Looking for Solutions to the Pitfalls of Developing Novel Antibacterials in an Economically Challenging System

Gilles Courtemanche, Rohini Wadanamby, Amritanjali Kiran, Luisa Toro-Alzate et autres

The increase in antibacterial resistance (ABR) currently equates in the minds of many with the distant fear that certain antibiotics will not work in 30 years on certain bacteria found in places the majority of us never go to. However, in reality, …

fr, lk, nl, ca, in (code pays fourni par la source)

Discovery of clinically approved drugs capable of inhibiting SARS-CoV-2 in vitro infection using a phenotypic screening strategy and network-analysis to predict their potential to treat covid-19

Douglas Ferreira Sales-Medina, Ludmila Rodrigues Pinto Ferreira, Lavínia Maria Dal’Mas Romera, Karolina Ribeiro Gonçalves et autres

Abstract The disease caused by SARS-CoV2, covid-19, rapidly spreads worldwide, causing the greatest threat to global public health in the last 100 years. This scenario has become catastrophic as there are no approved vaccines to prevent the disease, and the main measures …

br, gb, pl, fr (code pays fourni par la source)

Chagas Disease Drug Discovery: Multiparametric Lead Optimization against Trypanosoma cruzi in Acylaminobenzothiazole Series

Charlotte Fléau, Angel Marcelo Padilla, Juan Miguel-Siles, Maria Teresa Quesada-Campos et autres

Abstract Acylaminobenzothiazole hits were identified as potential inhibitors of Trypanosoma cruzi replication, a parasite responsible for Chagas disease. We selected compound 1 for lead optimization, aiming to improve in parallel its anti-T. cruzi activity (IC50 = 0.63 μM) and its human metabolic …

fr, us, es (code pays fourni par la source)

Metabolomics, lipidomics and proteomics profiling of myoblasts infected with Trypanosoma cruzi after treatment with different drugs against Chagas disease

K Hennig, Josephine Abi‐Ghanem, Andrei Bunescu, X. Meniche et autres

fr, gb, ch (code pays fourni par la source)

Peer Review Report For: Zika antiviral chemotherapy: identification of drugs and promising starting points for drug discovery from an FDA-approved library [version 1; peer review: 2 approved]

Bruno S. Pascoalino, Gilles Courtemanche, Marli Tenório Cordeiro, Laura H. V. G. Gil et autres

Background The recent epidemics of Zika virus (ZIKV) implicated it as the cause of serious and potentially lethal congenital conditions such microcephaly and other central nervous system defects, as well as the development of the Guillain-Barré syndrome in otherwise healthy patients. Recent …

br, fr (code pays fourni par la source)

Peer Review Report For: Zika antiviral chemotherapy: identification of drugs and promising starting points for drug discovery from an FDA-approved library [version 1; peer review: 2 approved]

Bruno S. Pascoalino, Gilles Courtemanche, Marli Tenório Cordeiro, Laura H. V. G. Gil et autres

Background The recent epidemics of Zika virus (ZIKV) implicated it as the cause of serious and potentially lethal congenital conditions such microcephaly and other central nervous system defects, as well as the development of the Guillain-Barré syndrome in otherwise healthy patients. Recent …

br, fr (code pays fourni par la source)

Zika antiviral chemotherapy: identification of drugs and promising starting points for drug discovery from an FDA-approved library

Bruno S. Pascoalino, Gilles Courtemanche, Marli Tenório Cordeiro, Laura H. V. G. Gil et autres

Background The recent epidemics of Zika virus (ZIKV) implicated it as the cause of serious and potentially lethal congenital conditions such microcephaly and other central nervous system defects, as well as the development of the Guillain-Barré syndrome in otherwise healthy patients. Recent …

br, fr (code pays fourni par la source)

Zika antiviral chemotherapy: identification of drugs and promising starting points for drug discovery from an FDA-approved library [version 1; referees: 2 approved]

Bruno S. Pascoalino, Gilles Courtemanche, Marli Tenório Cordeiro, Laura H. V. G. Gil et autres

Targeting DnaN for tuberculosis therapy using novel griselimycins

Angela Kling, Peer Lukat, Deepak V. Almeida, Armin Bauer et autres

The discovery of Streptomyces-produced streptomycin founded the age of tuberculosis therapy. Despite the subsequent development of a curative regimen for this disease, tuberculosis remains a worldwide problem, and the emergence of multidrug-resistant Mycobacterium tuberculosis has prioritized the need for new drugs. Here …

de, us, fr (code pays fourni par la source)